These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26625880)

  • 1. Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
    Deedwania PC; Stone PH; Fayyad RS; Laskey RE; Wilson DJ
    Drugs Aging; 2015 Dec; 32(12):1055-65. PubMed ID: 26625880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
    Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
    Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
    Athyros VG; Karagiannis A; Ganotakis ES; Paletas K; Nicolaou V; Bacharoudis G; Tziomalos K; Alexandrides T; Liberopoulos EN; Mikhailidis DP;
    Curr Med Res Opin; 2011 Aug; 27(8):1659-68. PubMed ID: 21714711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
    Ueshima K; Kasahara M; Koya D; Babazono T; Sato T; Imamoto M; Yasuno S; Fujimoto A; Tanaka S; Kimura G; Nakao K
    Clin Exp Nephrol; 2013 Apr; 17(2):211-7. PubMed ID: 22948416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D
    Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Elisaf M; Papageorgiou AA; Symeonidis AN; Pehlivanidis AN; Bouloukos VI; Milionis HJ; Mikhailidis DP;
    Am J Kidney Dis; 2004 Apr; 43(4):589-99. PubMed ID: 15042535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin.
    Ong KL; Waters DD; Fayyad R; Vogt L; Melamed S; DeMicco DA; Rye KA; Barter PJ
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
    Tonelli M; Moyé L; Sacks FM; Cole T; Curhan GC;
    J Am Soc Nephrol; 2003 Jun; 14(6):1605-13. PubMed ID: 12761262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
    Kose E; An T; Kikkawa A; Matsumoto Y; Hayashi H
    Biol Pharm Bull; 2014; 37(2):226-31. PubMed ID: 24492719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: subanalysis of the TRUTH study.
    Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Hibi K; Terashima M; Michishita I;
    Nephrology (Carlton); 2012 Sep; 17(7):628-35. PubMed ID: 22708952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
    Rahman M; Baimbridge C; Davis BR; Barzilay JI; Basile JN; Henriquez MA; Huml A; Kopyt N; Louis GT; Pressel SL; Rosendorff C; Sastrasinh S; Stanford C;
    Clin Nephrol; 2013 Oct; 80(4):235-48. PubMed ID: 23816477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
    Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Liberopoulos EN; Kakafika AI; Karagiannis A; Papageorgiou AA; Tziomalos K; Ganotakis ES; Elisaf M
    Nephrol Dial Transplant; 2007 Jan; 22(1):118-27. PubMed ID: 16998214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients.
    Suzuki H; Watanabe Y; Kumagai H; Shuto H
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):306-15. PubMed ID: 24280596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.